Glucopyranosyl lipid A - Immune Design

Drug Profile

Glucopyranosyl lipid A - Immune Design

Alternative Names: G 100; GLA; GLA-SE; Glucopyranosyl lipid adjuvant - Immune Design; ID-G100

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immune Design
  • Developer Immune Design; Merck & Co
  • Class Adjuvants; Antineoplastics; Immunotherapies; Small molecules
  • Mechanism of Action Immunostimulants; Toll-like receptor 4 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-Hodgkin's lymphoma
  • Phase I Merkel cell carcinoma; Soft tissue sarcoma

Most Recent Events

  • 10 Dec 2017 Updated efficacy, adverse events and pharmacodynamics data from a phase I/II trial in Non-Hodgkin's lymphoma released by Immune Design
  • 09 Dec 2017 Additional safety and efficacy data from a phase I/II trial in Non-Hodgkin's lymphoma presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-2017)
  • 01 Nov 2017 Updated efficacy data from a phase I/II trial for Non-Hodgkin's lymphoma released by Immune Design
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top